Multiparametric rapid screening of neuronal process pathology for drug target identification in HSP patient-specific neurons

[1]  Yuan Yuan,et al.  In silico identification of small molecules as novel LXR agonists for the treatment of cardiovascular disease and cancer , 2018, Journal of Molecular Modeling.

[2]  S. Züchner,et al.  Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial , 2017, Brain : a journal of neurology.

[3]  D. Timmann,et al.  Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78) , 2017, Brain : a journal of neurology.

[4]  A. D. Rodrigues,et al.  Discovery of Highly Potent Liver X Receptor β Agonists , 2016, ACS medicinal chemistry letters.

[5]  K. Behnia,et al.  Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils. , 2016, Cell Metabolism.

[6]  P. Baas,et al.  Microtubules and Growth Cones: Motors Drive the Turn , 2016, Trends in Neurosciences.

[7]  Zacharias Kohl,et al.  Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients , 2016, Annals of neurology.

[8]  R. Burke,et al.  Retrograde Axonal Degeneration in Parkinson Disease , 2016, Journal of Parkinson's disease.

[9]  J. Hjerling-Leffler,et al.  BCL11B/CTIP2 is highly expressed in GABAergic interneurons of the mouse somatosensory cortex , 2016, Journal of Chemical Neuroanatomy.

[10]  B. Wirth,et al.  Plastin 3 is upregulated in iPSC-derived motoneurons from asymptomatic SMN1-deleted individuals , 2016, Cellular and Molecular Life Sciences.

[11]  J. Solowska,et al.  Hereditary spastic paraplegia SPG4: what is known and not known about the disease. , 2015, Brain : a journal of neurology.

[12]  E. Rugarli,et al.  Spastin Binds to Lipid Droplets and Affects Lipid Metabolism , 2015, PLoS genetics.

[13]  F. Santorelli,et al.  Hereditary spastic paraplegia: Clinical-genetic characteristics and evolving molecular mechanisms , 2014, Experimental Neurology.

[14]  F. de Winter,et al.  ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease , 2014, Front. Neurosci..

[15]  Peter Tontonoz,et al.  Liver X receptors in lipid metabolism: opportunities for drug discovery , 2014, Nature Reviews Drug Discovery.

[16]  Paula Coutinho,et al.  The Global Epidemiology of Hereditary Ataxia and Spastic Paraplegia: A Systematic Review of Prevalence Studies , 2014, Neuroepidemiology.

[17]  C. Blackstone,et al.  Loss of Spastin Function Results in Disease‐Specific Axonal Defects in Human Pluripotent Stem Cell‐Based Models of Hereditary Spastic Paraplegia , 2014, Stem cells.

[18]  T. Ideker,et al.  Exome Sequencing Links Corticospinal Motor Neuron Disease to Common Neurodegenerative Disorders , 2014, Science.

[19]  F. Gage,et al.  Gene dosage-dependent rescue of HSP neurite defects in SPG4 patients’ neurons , 2013, Human molecular genetics.

[20]  N. Bresolin,et al.  Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. , 2014, Clinical therapeutics.

[21]  J. Hazan,et al.  An ESCRT–spastin interaction promotes fission of recycling tubules from the endosome , 2013, The Journal of cell biology.

[22]  G. Pigino,et al.  Axonal degeneration in Alzheimer's disease: When signaling abnormalities meet the axonal transport system , 2013, Experimental Neurology.

[23]  J. Fink,et al.  Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms , 2013, Acta Neuropathologica.

[24]  Xiaotang Fan,et al.  LXR Agonists: New Potential Therapeutic Drug for Neurodegenerative Diseases , 2013, Molecular Neurobiology.

[25]  M. Chopp,et al.  The Neurorestorative Benefit of GW3965 Treatment of Stroke in Mice , 2013, Stroke.

[26]  P. Mailly,et al.  Microtubule-targeting drugs rescue axonal swellings in cortical neurons from spastin knockout mice , 2012, Disease Models & Mechanisms.

[27]  Lauren I. Siniscalchi,et al.  Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions , 2012, Nature Protocols.

[28]  C. Blackstone,et al.  Cellular pathways of hereditary spastic paraplegia. , 2012, Annual review of neuroscience.

[29]  Charles C Hong,et al.  DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: comparison of PAX6 and SOX1 expression during neural induction. , 2012, ACS chemical neuroscience.

[30]  E. Hur,et al.  Growing the growth cone: remodeling the cytoskeleton to promote axon regeneration , 2012, Trends in Neurosciences.

[31]  Peter Kirwan,et al.  Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses , 2012, Nature Neuroscience.

[32]  G. Valen,et al.  Activation of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia–reperfusion injury , 2012, Basic Research in Cardiology.

[33]  Matilde Inglese,et al.  Axonal damage in multiple sclerosis. , 2011, The Mount Sinai journal of medicine, New York.

[34]  J. Wood,et al.  Genetic and chemical modulation of spastin-dependent axon outgrowth in zebrafish embryos indicates a role for impaired microtubule dynamics in hereditary spastic paraplegia , 2010, Disease Models & Mechanisms.

[35]  C. Wellington,et al.  ATP-binding Cassette Transporter A1 Mediates the Beneficial Effects of the Liver X Receptor Agonist GW3965 on Object Recognition Memory and Amyloid Burden in Amyloid Precursor Protein/Presenilin 1 Mice* , 2010, The Journal of Biological Chemistry.

[36]  L. Martin.  Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. , 2010, IDrugs : the investigational drugs journal.

[37]  J. Solowska,et al.  Evaluation of loss of function as an explanation for SPG4-based hereditary spastic paraplegia. , 2010, Human molecular genetics.

[38]  C. Blackstone,et al.  Further assembly required: construction and dynamics of the endoplasmic reticulum network , 2010, EMBO reports.

[39]  N. Siddique,et al.  Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis , 2010, Journal of Lipid Research.

[40]  C. Lindsley,et al.  In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. , 2010, ACS chemical biology.

[41]  P. Berna,et al.  Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound , 2010, Pharmaceuticals.

[42]  Xinnan Wang,et al.  The hereditary spastic paraplegia proteins NIPA1, spastin and spartin are inhibitors of mammalian BMP signalling , 2009, Human molecular genetics.

[43]  S. Wharton,et al.  Direct evidence for axonal transport defects in a novel mouse model of mutant spastin‐induced hereditary spastic paraplegia (HSP) and human HSP patients , 2009, Journal of neurochemistry.

[44]  Jonathan Popko,et al.  Automated analysis of NeuronJ tracing data , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[45]  E. Rugarli,et al.  Pleiotropic effects of spastin on neurite growth depending on expression levels , 2009, Journal of neurochemistry.

[46]  J. Luzio,et al.  Spastin Couples Microtubule Severing to Membrane Traffic in Completion of Cytokinesis and Secretion , 2008, Traffic.

[47]  Christos Proukakis,et al.  Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms , 2008, The Lancet Neurology.

[48]  B. Himes,et al.  Quantitative and Functional Analyses of Spastin in the Nervous System: Implications for Hereditary Spastic Paraplegia , 2008, The Journal of Neuroscience.

[49]  M. Pool,et al.  NeuriteTracer: A novel ImageJ plugin for automated quantification of neurite outgrowth , 2008, Journal of Neuroscience Methods.

[50]  F. Bradke,et al.  Microtubule stabilization specifies initial neuronal polarization , 2008, The Journal of cell biology.

[51]  Ronald D. Vale,et al.  Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin , 2008, Nature.

[52]  J. Boudreaux,et al.  Nuclear localization of liver X receptor α and β is differentially regulated , 2007 .

[53]  J. Boudreaux,et al.  Nuclear localization of liver X receptor alpha and beta is differentially regulated. , 2007, Journal of cellular biochemistry.

[54]  J. Hauw,et al.  A mutation of spastin is responsible for swellings and impairment of transport in a region of axon characterized by changes in microtubule composition. , 2006, Human molecular genetics.

[55]  P. Shaw,et al.  The microtubule-severing protein Spastin is essential for axon outgrowth in the zebrafish embryo. , 2006, Human molecular genetics.

[56]  R. Conwit,et al.  Neuroprotective agents for clinical trials in ALS , 2006, Neurology.

[57]  K. Zou,et al.  Cholesterol-mediated Neurite Outgrowth Is Differently Regulated between Cortical and Hippocampal Neurons* , 2005, Journal of Biological Chemistry.

[58]  G. Meister,et al.  Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. , 2005, Genes & development.

[59]  J. Gustafsson,et al.  Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Sanderson,et al.  The hereditary spastic paraplegia protein spastin interacts with the ESCRT-III complex-associated endosomal protein CHMP1B. , 2005, Human molecular genetics.

[61]  P. Dollé,et al.  CTIP1 and CTIP2 are differentially expressed during mouse embryogenesis. , 2004, Gene expression patterns : GEP.

[62]  T. Kirchgessner,et al.  Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator Published, JLR Papers in Press, June 1, 2004. DOI 10.1194/jlr.M300450-JLR200 , 2004, Journal of Lipid Research.

[63]  Timothy J Mitchison,et al.  A Novel Action of Histone Deacetylase Inhibitors in a Protein Aggresome Disease Model , 2004, Current Biology.

[64]  P. Gordon-Weeks.  Microtubules and growth cone function. , 2004, Journal of neurobiology.

[65]  E. Elson,et al.  Effects of cytochalasin D and latrunculin B on mechanical properties of cells. , 2001, Journal of cell science.

[66]  A. Reis,et al.  Hereditary spastic paraplegia caused by mutations in the SPG4 gene , 2000, European Journal of Human Genetics.

[67]  S. Hinderer,et al.  Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. , 2000, Brain : a journal of neurology.

[68]  Bertrand Fontaine,et al.  Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia , 1999, Nature Genetics.

[69]  C. Dotti,et al.  The role of local actin instability in axon formation. , 1999, Science.

[70]  L. Amos,et al.  How Taxol stabilises microtubule structure. , 1999, Chemistry & biology.

[71]  R. Ledeen,et al.  Gangliosides and Other Lipids of the Growth Cone Membrane , 1988, Journal of neurochemistry.

[72]  Thomas D. Pollard,et al.  Mechanism of action of cytochalasin B on actin , 1980, Cell.